Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years, a top executive told Reuters ...

In what Science magazine has dubbed “Novo Nordisk’s Canadian Mistake,” Ozempic is soon to come off patent in Canada, opening ...

Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to ...

Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...

In January 2026, the Canadian patent for Ozempic will expire, paving the way for cheap generic versions of the semaglutide ...

There’s a perception that Ozempic, Wegovy and Zepbound are all you need to live a healthier life. But diet and exercise still ...

Over 60 novel drug candidates are in late-stage clinical trials in China, and these will potentially compete directly with US ...

It comes in a small pen-like device that ... issues,” notes Dr Pillai. Generic versions are expected in the next couple of years, and Indian pharmaceutical companies are preparing for wider ...

Novo has, notably, kept up with its patent fees in the US, and generic semaglutide won't hit American shelves until at least 2032 — but as Saynor alluded to, they might be able to drive up to ...

Semaglutide, widely used to treat diabetes and obesity, was associated with more than double the risk of developing neovascular age-related macular degeneration (nAMD) in older patients with ...

Semaglutide, available under the brand names Ozempic and Wegovy, may help decrease the risk of major adverse cardiovascular events after just six months of starting the medication, a new study ...

The FDA has accepted for review the New Drug Application for a 25 mg oral formulation of semaglutide for chronic weight management.